New hope for rare leukemia: Four-Drug cocktail targets cancer cells
NCT ID NCT07652905
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new drug combination for adults newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The treatment includes CM336 (a bispecific antibody) plus three other drugs. The study aims to see how many patients achieve deep remission and to monitor side effects. All 24 participants will receive the same treatment; there is no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CM336 (a bispecific antibody) combined with isatuximab, lenalidomide, and bortezomib
- What this could lead to
- If successful, this combination could offer a more effective treatment option for a rare and aggressive blood cancer, potentially leading to longer remission and survival.
- What could go wrong
- This is a small, early-phase trial with no comparison group, so results may not be definitive. The drug combination may cause significant side effects, and the benefit may not be confirmed in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL LEUKEMIA (PCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.